Others have shown that blocking IL-6 with tocilizumab (an anti-IL-6 receptor (IL-6R) monoclonal antibody) in patients with RA inhibited these senescent-like B cells and improved clinical symptoms, further supporting a pathogenic role for this B cell subset.42 This evidence concerns the gene IL6R and rheumatoid arthritis.